argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
globenewswire.com
Want to monitor AGB2.DE?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor AGB2.DENo company information available
No data available